Mr. Philippe Dubuc reports

THERATECHNOLOGIES ANNOUNCES AMENDMENTS TO ITS TERM LOAN FACILITY WITH AFFILIATES OF MARATHON ASSET MANAGEMENT

Theratechnologies Inc. has entered into an agreement with certain funds and accounts for which Marathon Asset Management LP acts as investment manager to amend some of the terms and conditions of its credit agreement entered into in July, 2022, to lower the minimum liquidity the company must maintain at any time to $15-million (U.S.) from $20-million (U.S.).

The amendments provide, inter alia, that the company must hold this minimum amount of liquidity at all times up to and until Oct. 31, 2023, and must comply with all of the other terms and conditions of the credit agreement. The company is taking the necessary steps to ensure continued compliance with the liquidity covenant in the future.

Under the credit agreement, the company was required to hold a minimum of $20-million (U.S.) at all times in cash and other liquid investments. The terms and conditions related to the obligation to maintain a minimum amount of liquidity under the credit agreement have previously been amended, and the last amendment was valid until July 28, 2023.

"This amendment entered into with Marathon will allow us to continue focusing on the growth of our business with the aim of achieving a positive adjusted [earnings before interest, taxes, depreciation and amortization] by the current fiscal year-end," said Philippe Dubuc, senior vice-president and chief financial officer, Theratechnologies.

About Theratechnologies Inc.

Theratechnologies (Toronto Stock Exchange: TH) (Nasdaq: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs.

We seek Safe Harbor.